TAILIEUCHUNG - Visualizing the dynamics of genetic profile in breast cancer treatment: A better way to explain why a drug could be repurposed: A riview

In this work, we further enhance our computational framework for breast cancer drug repurposing by visualizing the prospected dynamic gene expression after the treatment. Practically, the most challenging problem in drug repurposing is to prioritize the list of drugs for further in vivo validation and entering clinical trials. | Journal of military pharmaco-medicine no1-2019 VISUALIZING THE DYNAMICS OF GENETIC PROFILE IN BREAST CANCER TREATMENT: A BETTER WAY TO EXPLAIN WHY A DRUG COULD BE REPURPOSED: A RIVIEW Nguyen Thanh Minh1; Nguyen Thi Kim Tran2; Jake Yue Chen1 SUMMARY In this work, we further enhance our computational framework for breast cancer drug repurposing by visualizing the prospected dynamic gene expression after the treatment. Practically, the most challenging problem in drug repurposing is to prioritize the list of drugs for further in vivo validation and entering clinical trials. In drug repurposing, the possible candidate drugs could be between fifty and several hundreds, depending on different approaches for candidate selection. In contrast, due to the budget and safety constraints, a repurposing clinical trial usually contain only one or a few drugs. In a prior work, we achieved some successes in solving the prioritization problem. However, we were not able to provide detailed and easy to understand explanation on the prospected dynamic changes of the genetic information. The visualization presented in this work would help achieving this task. The complete framework of computing and visualization helps the doctor to select one repurposed strategy: Targeting ACHE gene in breast cancer for in vivo validation with promising result. * Keywords: Breast cancer; Drug; Genetics. INTRODUCTION Drug repurposing (also called drug repositioning) has become one of the most active areas in pharmacology since last decade because this approach could significantly reduce the cost and time to invent a new treatment. Before drug repurposing research became active, it was expected to take about 15 years and $ - $1 billion to invent a new drug [1], due to many tests and clinical trials in order to be commercially approved by American Food and Drug Administration (FDA). It is expected that the failure probability during clinical trials is about [2]. Briefly, drug repurposing finds .

• Y khoa - Dược
• Breast cancer
• Computational framework
• Drug repurposing
• Dynamic gene expression
• Entering clinical trials
• BMC Cancer
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Breast cancer management
• Gross anatomy
• The breast
• Breast cancer epidemiology
• Hereditary breast cancer genetics
• Prediction techniques
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Breast specific gamma imaging
• Diagnosing breast cancer during
• Ductal carcinoma in situ
• DNA methylation
• Breast epithelial cells
• Breast cancer campaign tissue bank
• Breast milk
• Axillary lymph node dissection
• Breast cancer related lymphedema
• Breast lymphatics level
• Ovarian cancer
• Mauritanian breast cancer patients
• Triple negative breast cancer
• Molecular subtype
• Cholesterol observed
• Female breast cancer
• Breast feeding
• World Health Organization
• Inflammatory breast cancer
• Case comparison study
• Family history of breast cancer
• Breast cancer risk factors
• Multiplex IBC families
• Carcinoma associated fibroblasts
• Breast cancer pathogenesis
• Breast cancer cell biology
• Cytokine molecules mediating
• Stage IV breast cancer
• Metastatic breast cancer
• Diagnostic marker
• Searching reliable
• Protein cancer biomarkers
• Breast fluid secretome
• breast cancer second edition
• Breast Sonography
• Radionuclide Imaging of the Breast
• Mammography
• Breast Reconstruction
• Chemotherapy for Breast Cancer
• Breast imaging
• Breast pathology
• Breast soft tissue
• Breast cancers
• Breast tumorigenesis
• Non steroidal anti inflammatory drug
• Hormone receptor positive breast cancer
• HER2 positive breast cancer
• Aggressive tumor phenotype
• Health care
• Including increased frequency
• Polygenic risk score
• Single nucleotide polymorphisms
• Artifcial neural network
• Estrogen receptor negative breast cancer
• Mammographic breast density
• Breast cancer risk
• Atypical hyperplasia
• Established risk factors
• Non melanoma skin cancer
• Metastatic cancer
• Reduce ethnic
• Multivariate models adjusting
• Cancer survivorship
• Cancer prevalence
• Statistical projection
• Toll like receptor 4
• +3725G C polymorphism
• Egyptian breast cancer atients
• Breast cancer cases than controls
• Post treatment breast cancer patients
• Pre treatment breast cancer
• Extraaxilary nodes
• Distance metastases
• Breast cancer cell lines
• Breast tumor subtypes
• Topoisomerase I
• Camptothecin sensivity
• Epithelial type
• Triplenegative breast carcinomas
• N terminal p63 isoforms